RNAi therapeutic and its innovative biotechnological evolution
Abstract Recently, United States Food and Drug Administration (FDA) and European
Commission (EC) approved Alnylam Pharmaceuticals' RNA interference (RNAi) therapeutic …
Commission (EC) approved Alnylam Pharmaceuticals' RNA interference (RNAi) therapeutic …
[HTML][HTML] Improved nucleic acid therapy with advanced nanoscale biotechnology
Y Weng, Q Huang, C Li, Y Yang, X Wang, J Yu… - … Therapy-Nucleic Acids, 2020 - cell.com
Due to a series of systemic and intracellular obstacles in nucleic acid (NA) therapy, including
fast degradation in blood, renal clearance, poor cellular uptake, and inefficient endosomal …
fast degradation in blood, renal clearance, poor cellular uptake, and inefficient endosomal …
microRNA‐101 is a potent inhibitor of autophagy
LB Frankel, J Wen, M Lees, M Høyer‐Hansen… - The EMBO …, 2011 - embopress.org
Autophagy is an evolutionarily conserved mechanism of cellular self‐digestion in which
proteins and organelles are degraded through delivery to lysosomes. Defects in this process …
proteins and organelles are degraded through delivery to lysosomes. Defects in this process …
RNA interference and cancer therapy
Z Wang, DD Rao, N Senzer, J Nemunaitis - Pharmaceutical research, 2011 - Springer
Since its discovery in 1998, RNA interference (RNAi) has revolutionized basic and clinical
research. Small RNAs, including small interfering RNA (siRNA), short hairpin RNA (shRNA) …
research. Small RNAs, including small interfering RNA (siRNA), short hairpin RNA (shRNA) …
[HTML][HTML] Delivery of therapeutic oligonucleotides in nanoscale
Therapeutic oligonucleotides (TOs) represent one of the most promising drug candidates in
the targeted cancer treatment due to their high specificity and capability of modulating …
the targeted cancer treatment due to their high specificity and capability of modulating …
Gain-of-function mutant p53 downregulates miR-223 contributing to chemoresistance of cultured tumor cells
S Masciarelli, G Fontemaggi, S Di Agostino, S Donzelli… - Oncogene, 2014 - nature.com
Mutant p53 proteins are expressed at high frequency in human tumors and are associated
with poor clinical prognosis and resistance to chemotherapeutic treatments. Here we show …
with poor clinical prognosis and resistance to chemotherapeutic treatments. Here we show …
MicroRNAs in autophagy and their emerging roles in crosstalk with apoptosis
J Xu, Y Wang, X Tan, H Jing - Autophagy, 2012 - Taylor & Francis
Macroautophagy (hereafter referred to as autophagy) is an evolutionarily conserved self-
degradative process, which involves the regular turnover of cellular components via …
degradative process, which involves the regular turnover of cellular components via …
Short hairpin RNA-mediated gene silencing
LS Lambeth, CA Smith - siRNA Design: Methods and Protocols, 2013 - Springer
Since the first application of RNA interference (RNAi) in mammalian cells, the expression of
short hairpin RNAs (shRNAs) for targeted gene silencing has become a benchmark …
short hairpin RNAs (shRNAs) for targeted gene silencing has become a benchmark …
[HTML][HTML] Stathmin-dependent molecular targeting therapy for malignant tumor: the latest 5 years' discoveries and developments
R Biaoxue, C Xiguang, L Hua, Y Shuanying - Journal of translational …, 2016 - Springer
Abstract Knowledge of the molecular mechanisms on malignant tumors is very critical for the
development of new treatment strategies like molecularly targeted therapies. In last 5 years …
development of new treatment strategies like molecularly targeted therapies. In last 5 years …
RNAi in clinical studies
P Kubowicz, D Zelaszczyk… - Current medicinal …, 2013 - ingentaconnect.com
RNA interference (RNAi) is an efficient process of posttranscriptional gene silencing. In
recent years it has been developed into a new technology in biopharmaceutical fields of …
recent years it has been developed into a new technology in biopharmaceutical fields of …